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ORIGINAL RESEARCHRETROLECTIVE STUDIES ON THE SURVIVAL OF CANCER PATIENTS TREATED WITH
MISTLETOE EXTRACTS: A META-ANALYSISThomas Ostermann, PhD, MSc,1# and Arndt Büssing, PhD, MD1Background: Studies reveal that patients with cancer are ac-
tively seeking supportive treatments andmay use distinct coping
strategies that might be helpful to extend survival time. In this
respect, retrolective studies have been applied to examine the
therapeutic potential of adjuvant mistletoe treatment.
Material and Methods: The databases PubMed, EMBASE,
AMED, and CAMbase were used to identify retrolective studies
in mistletoe treatment. In addition to a review, we also per-
formed a meta-analysis with respect to cancer patients’ survival
time by a random effects model. Overall estimates of treatment
effects were displayed with a forest plot.
Results: A total of 17 articles met the inclusion criteria. From
these, 10 duplicates and 3 descriptive literature and popular
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Open access under CC BY-NC-ND license.articles had to be removed, leaving 4 retrolective studies on
mistletoe preparations and patients’ survival conducted between
1985 and 2002, with a total of 3.324 patients (2.454 per protocol)
recruited in 17 to 35 German and Swiss hospitals, wards, and
private practices. Meta-analysis revealed a moderate overall ef-
fect of hazard ratios 0.59 (95% confidence interval 0.50-0.70) in
favor of mistletoe treatment.
Discussion: Although we found a positive treatment effect,
there are several methodological limitations with respect to the
retrolective study design.
Key words: Mistletoe, survival, cancer, retrolective studies(Explore 2012; 8:277-281. © 2012 Elsevier Inc.)
Open access under CC BY-NC-ND license.INTRODUCTION
Studies reveal that patients with cancer are actively seeking sup-
portive treatments and may use distinct coping strategies that
might be helpful to extend survival time, gain a better quality of
life, or relieve pain.1,2 Alongside conventional treatment strate-
ies, integrative and complementary approaches have been de-
eloped to help patients achieve these goals. In several studies,
esearchers have explored the effects ofmindfulness-based stress-
eduction programs or yoga for improving mood and quality of
ife of patients with cancer.3-5 With regard to pharmaceutical
herapies, extracts from Viscum album (VA-E), the European
hite-berry mistletoe, are widely used as an adjuvant treatment
n patients with cancer, particularly in Germany and Switzer-
and.6 Rudolf Steiner (1861-1925), the founder of anthropo-
sophic medicine, was a strong advocate of using mistletoe ex-
tracts as a cancer treatment,7 and in the last 20 years, an increase
n clinical evaluations of mistletoe extracts as an adjuvant cancer
reatment has been observed, documented by several studies on
heir use and their clinical effects, particularly on survival and
uality of life.8-12
However, the recruitment of patients for randomized con-
trolled trials (RCTs) remains a major problem in all of the afore-
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Herdecke, Germanymentioned examples because some physicians are convinced
that VA-Es have beneficial effects and thus object to their pa-
tients being randomized as the result of ethical considerations.
Also, the patientsmay have a strong preference to be treated with
VA-E because they have heard that these drug extracts might be
beneficial and thus actively choose medical wards to be treated
with VA-E; therefore, randomization is thwarted by these pa-
tient preferences.13
The question arises how the effectiveness of mistletoe treat-
ment can be proven in a prospectively controlled study with-
out strictly relying on the putative “gold standard” of an RCT.
One attempt first described by Feinstein in 1985 was to con-
duct so-called “retrolective” studies.14 Retrolective, according
to the definition of Feinstein, means that the treatment has
already been started before the onset of the study, and data
are collected prospectively. Individual treatment, therefore, is
not disturbed by randomization (against patients’ prefer-
ences), and group comparability is achieved by matching al-
gorithms.
Particularly in chronic long-term diseases like type II diabe-
tes,15 this type of study has become a popular alternative to
conventional study outlines. Regarding cancer treatment, retro-
lective studies have been applied in the assessment of disease risk
estimation of hereditary nonpolyposis colorectal cancer -related
cancers,16 to prove the efficiency of neoadjuvant treatment in
locally advanced squamous cell esophageal cancer,17 or in the
valuation of impact of complementary oral enzyme application
n various cancer types on the postoperative treatment re-
ults.18-20 In integrative cancer therapy, retrolective studies have
been applied to adjuvant mistletoe treatment quite often.21-24 In
his article, we review and analyze the results of such studies in a
eta-analysis.
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Search Strategy
The electronic databases PubMED, EMBASE, AMED, and
CAMbase were used to identify retrolective studies of mistletoe
treatment of the last 25 years. The search terms were “Mistletoe
and “Retrolective,” and their respective translations to German.
In all articles found this way the reference lists were checked for
further relevant publications. The complete search was per-
formed between January 2010 and February 2011.
Selection Criteria
All potentially eligible studies were retrieved, and the full-text
articles were reviewed to determine whether they met the inclu-
sion criteria. Inclusion criteria were treatment of cancer and
mistletoe extracts on the one hand and a retrolective study de-
sign on the other hand. We excluded papers that duplicated the
study results of previous papers and also descriptive literature
and popular articles.
Analysis of Data
Review authors assessed the trials for their inclusion in the re-
view. They took part in the extraction of data and assessment of
methodological quality. Disagreements were resolved by con-
sensus. Methodological quality of the studies was graded by the
following checklist derived from the consort statement (rater
assessment): adequate description of the design (prospective,
multicenter study etc), accrual (blinding, randomization,
matched pairs, drop outs, etc), description of the intervention
(application, duration and frequency, control group interven-
tion), patient characteristics, and description of cancer grad-
ing and tumor localization.
Statistical Analysis
In addition to a review of published evidence, we also performed
a meta-analysis with respect to cancer patients’ survival time.
When a trial was found to be eligible, survival data were ex-
tracted and entered into a data form and converted into hazard
ratios (HR) and their standard errors by use of the standard
formulas given in Borenstein and Hedgesl25 with the use of
Review-Manager Version 5. A HR  1 indicated superiority of
treatment with mistletoe extracts, whereas a HR  1 indicated
superiority of the control condition. Heterogeneity between tri-
als was assessed by standard chi-square tests and the I2-coeffi-
ient measuring the percentage of total variation across studies
ue to true heterogeneity rather than chance. Overall estimates
f the treatment effect were obtained from random effects meta-
nalysis. Results were displayed with a forest plot. Because of the
xpected small number of eligible studies, further analysis by
eans of metaregression was omitted.
ESULTS
e found a total of 17 articles that met the inclusion criteria.
fter removing the duplicates (n 10) and excluding descriptive
literature and popular articles (n 3), we identified four relevant
articles. These studies were controlledmulticenter cohort studies
conducted between 1985 and 2002 with a total of 3.324 patients
278 EXPLORE September/October 2012, Vol. 8, No. 5(2.454 per protocol) recruited in 17 to 35 German and Swiss
hospitals, wards, and private practices. Both control and inter-
vention groups—according to descriptions in the original arti-
cles—received standard oncological treatment, whereas the inter-
vention groups received in addition the commercially available
fermented VA-E Iscador® (Weleda AG, Basel, CH - 4052, Swit-
zerland).
In the first study, Bock et al (2004)21 evaluated the therapeutic
efficacy and safety of subcutaneous VA-E injections of at least
three months in primary, nonmetastatic breast cancer patients
(Union for International Cancer Control [UICC] stage I-III)
applied in addition to conventional adjuvant oncological
chemo-, radio-, and hormonal therapy. From 1988 to 2000 a
total of 1,442 patients from 16 centers in Germany and Switzer-
land were enrolled; nine of the centers were clinics or hospitals.
The overall estimated survival time was significantly longer in
the treatment group, leading to a weak HR of 0.46 (95% confi-
dence interval [95% CI] .22-.96, P  .038). Systemic adverse
drug reactions (ADRs) attributed to the VA-E treatment were de-
scribed as occurring in 0.8% and local ADRs in 17.3% of the pa-
tients. The severity of the ADRs was mild to intermediate (World
HealthOrganization/CommonToxicityCriteria grade 1-2). Severe
mistletoe extract therapy-related ADRs or tumor enhancement
were not observed.
One year later in 2005, Augustin et al22 conducted a study
nrolling 686 patients diagnosed with primary intermediate to
igh-risk malignant melanoma (Union for International Cancer
ontrol/American Joint Committee on Cancer stage II and III)
etween 1985 and 2001. Here, the number of centers doubled to
5. After adjusting for potential confounders, we found a weak
R of 0.41 (95% CI 0.23-0.71, P  .002) favoring the VA-E.
In 2009, Friedel et al23 conducted a retrolective study from the
ame data repository, this time enrolling 804 patients with non-
etastatic colorectal cancer treated between 1993 and 2002.
gain, adjuvant treatment regimen with Iscador was comparable
ith the study by Bock et al.21 In this study, a moderate HR of
0.68 (95% CI 0.51-0.92, P .013) indicated a longer disease-free
eriod and a survival benefit for patients treated with VA-E.
Finally, Matthes et al24 published a retrolective study con-
ducted between 1993 and 2002 in 396 pancreatic cancer patients
with UICC stages I-IV undergoing curative intent resection and
adjuvant chemotherapy in 2010. The adjusted HR 0.52 (95% CI
0.40-0.68, P  .001) indicated a moderate effect in favor of the
VA-E treatment. Table 1 summarizes the characteristics of the
studies.
Themeta-analysis of these four studies indicates a high homo-
geneity in the effects of mistletoe treatment in various types of
cancer (chi-square 2.38; I2 0.001). In addition, themoderate
overall effect of 0.59 (95% CI 0.50-0.70) favors mistletoe treat-
ment (Figure 1). The effect still remains stable with effect sizes
between 0.51 and 0.69 if one of the studies would be deleted.
DISCUSSION
The findings from retrolective studies (which had a high homo-
geneity in the effects of VA-E treatment in various types of
cancer) indicate that the adjunctive application of mistletoe ex-
tracts is an effective treatment (overall effect of HR 0.59; 95%CI
Study Analysis of Mistletoe Treatment for Cancer Patients
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I0.50-0.70). A current systematic review of VA-E application
stated a significantly greater survival rate of cancer patients in
various study types11 with an overall HR 0.59 (95%CI 0.53-0.66,
 .0001), which is similar to the current finding. However, the
eview also showed that the effects may be influenced by the
esign of the studies, ie, randomized studies showed less effects
han nonrandomized studies (ratio of HR 1.24, 95% CI 0.79-
.92, P .35), and matched-pair studies gave significantly better
esults than others (ratio of HR 0.33; 95% CI 0.17-0.65, P 
0012).
The studies in this meta-analysis have a multicentric, epide-
iological cohort design with parallel groups without an inter-
ention in the control group. All (future) data were assessed
ithout actual knowledge of the course of disease; the theoreti-
able 1. Characteristics of Retrolective Mistletoe Studies
Bock 200421
N (VA-E vs control) 1442 (710/732)
Number of centers 16
Time frame 1988-2000
Type of cancer Breast
Intervention (Iscador/control), %
Radiation 43.9/75.7
Chemotherapy 32.8/23.2
Surgery All
Others 50.1/50.3 (hormones)
ICC I-III
ollow-up, mo
Iscador 66
Control 60
scador (host tree), %
Pinus 31.4
Quercus —
Malus 44.9
Combinations 23.7
edian duration, mo 52
nterventional adverse drug reactions, %
Iscador 25.3
Control 63.1Figure 1. Forest plot of
Study Analysis of Mistletoe Treatment for Cancer Patientsal ‘start’ of the study dates back to the time of tumor diagnosis
nd surgical intervention (past). Finally, the data of the treat-
ent group were compared with an untreated control group. An
nspection plan describes the criteria for inclusion or exclusion
f patients (see Augustin et al22 for details). Thus, several limi-
ations of our results have to be discussed.
imitations
heoretically, there are a variety of limitations given from the
tudy design, ie, selection of centers, selection of patients, non-
omparability of cohorts (treatment versus control) etc. With
espect to the process of patient allocation, Bock et al21 de-
cribed a random sample of putative centers willing to partici-
ate; however, the final criteria remain unclear (ie, nine primary
Augustin 200522 Friedel 200923 Matthes 201024
686 (329/357) 804 (429/375) 396 (201/195)
35 26 17
1985-2001 1993-2002 1993-2002
elanoma Colorectal Pancreatic
7.9/5.9 17.8/16.5% 4.5/18.5
10.0/5.9 53.3/53.6 71.6/43.6
ll All 69.2/48.2
2.1/19.8 (immunotherapy) — —
II-III I-III I-IV
81 58 15
51 51 10
83.3 — —
— 52.7 37.3
— 37.8 36.8
16.7 9.5 25.9
30 52 15
— 19.1 13.7
— 48.3 48.9M
A
1retrolective studies.
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lcare and postoperative care clinics/hospitals and seven oncolog-
ical treatment care centers). Further, in the studies of Bock et al21
and Augustin et al,22 the authors stated that “in the centres the
edical records were obtained for all those patients treated from
988 to 2000 as part of postsurgical breast cancer care”21 or
etween 1985 and 2001 for the melanoma patients.22 With re-
pect to patients’ selection, they stated further: “Patient data
ere included in the study chronologically and without any
urther selection.”21,22
Particularly in Bock et al,21 the authors were aware that the
llocation to the study and control group was not randomized,
nd thus the groups could differ with respect to baseline and
reatment conditions. To handle this, they performed “multivar-
ate adjustment for the baseline inhomogeneity, treatment mea-
ures and other influential factors (confounders) [. . .] using lo-
istic regression (for ADRs and symptoms) or Cox proportional
azard regression (for survival).” Nevertheless, in Bock et al,21
the study and control group differed with respect to several
relevant characteristics, some in favor of the controls, others in
favor of the study group. Interestingly the patients in the study
of Augustin et al22 were much better balanced. Unfortunately,
hese observations were only partly discussed in the original
apers.
Augustin et al22 critically discussed potential risks of bias and
described the attempts to avoid them in their study. They per-
formed a multivariate adjustment and various sensitivity analy-
ses to exclude a model or covariate dependent bias.
However, we cannot exclude the possibility that additional
treatments were used in the centers in which VA-E was used,
treatments that often are used as integral part of complex inter-
vention strategies. The authors just stated that “in the centres
either the mistletoe extract was used as complementary treat-
ment in addition to conventional therapy or conventional
treatment only was used.” Further supportive treatment op-
tions (which are routine in centers with an anthroposophic
background) might have been applied and also could have
influenced the results. Moreover, the authors mentioned that
“there were no restrictions on the type of conventional treat-
ment or other additional measures such as physiotherapy.”22
Unfortunately, except of physiotherapy additional treat-
ments were not recorded systematically. We thus cannot ex-
clude the possibility that other treatments may have contrib-
uted to the reported effects attributed to the VA-E.
Several limitations were reported also in other retrolective
studies. Kopciuk et al16 critically mentioned the possibilities of
inaccuracies in cancer diagnosis or screening history. Similar to
the studies included in our analysis, cases or dates of entry into
screening programs could not be confirmed. This was also the
major limitation in another study of Wiese et al26 from 2010,
here a prompt sheet for the investigation of data from medical
ocuments from emergency medical service teams and regular
mergency was not used.
Other prospective epidemiological studies in the field of com-
lementary cancer reported similar limitations: In 2001, Gros-
arth-Maticek et al27 pointed out that in their study of 10,226
ancer patients “study workers responsible were not blinded as
o which patient was treated with Iscador” and thus a selection
ias might have been introduced in matching the patients. In o
280 EXPLORE September/October 2012, Vol. 8, No. 5nother study of Grossarth-Maticek et al from 2006 the authors
ommit that the generalizability of their findings “might be
imited by the fact that the inclusion and exclusion criteria were
either very precise nor always explicitly formulated in ad-
ance.”28
Currently there are efforts among clinicians to examine exist-
ing clinical data as a source for information regarding efficacy of
VA-E treatment. To raise the level of evidence this has led to the
use of retrolective designs which in fulfillment of the evidence-
based medicine (EBM) criteria as epidemiological cohort studies
with a parallel group designs can be considered as studies with
class IIb level of evidence and, as such, are acceptable to Euro-
pean Union nations as demonstrations of efficacy.
However, according to Edler “selection and information bias
in favour of the mistletoe treatment and to the disadvantage of
the control cannot be ruled out in some cases.”29 Indeed, apart
from already-known specific methodological problems in meta-
analyses (ie unequality in indications, therapeutic regimens,
time frames, and center effects) retrolective studies also have
parameters such as different starting points, flaws, and inequal-
ities in documentation and monitoring. Although not all factors
influencing the therapeutic outcome can be determined a priori,
statistical methods like propensity score adjustment for the
known confounders may compensate their effects to a certain
extend as was shown in the study of Augustin et al22. To what
extend this procedure due to intercorrelation of confounders
may also be able to control for “hidden biases” as proposed by
Schneider30 or may influence the hazard ratio can only be hy-
othesized.
From the legal perspective, however, the Federal Institute for
rugs and Medical Devices (Bundesinstitut für Arzneimittel
nd Medizinprodukte [BfArM]) notification of 04/12/1998
tates that “As long as scientifically planned and carefully carried
ut, this type of post-marketing surveillance study may be incor-
orated into the benefit/risk assessment as ‘other scientific find-
ngs’ according to Article 22, Paragraph 3 of the German Medi-
ines Act (AMG)” (quoted from Schneider30). Therefore, a
roperly planned and conducted retrolective study may not
nly give insights in daily clinical practice of established thera-
ies but may also add on their evidence without disturbing daily
linical routine. This was also confirmed in this meta-analysis,
hich demonstrates that the global effect size of retrolective
tudies did not differ from the effects found in a former meta-
nalysis in which all studies of Iscador VA-E extracts were in-
luded. Thus, this meta-analysis mainly demonstrated compara-
ility of effects but cannot comment on the appropriateness or
uperiority of RCTs and retrolective studies. This was also
ointed out by Schneider et al30 in stating that retrolective stud-
es “should be regarded neither as substitutes for nor alternatives
o controlled clinical trials.”
ONCLUSIONS
lthough findings of retrolective studies in mistletoe treatment
how effects comparable with the findings of a recent meta-
nalysis, including studies with various designs, there are several
imitations in the current retrolective design. From a method-
logical point of view, these limitations indicate that the con-
Study Analysis of Mistletoe Treatment for Cancer Patients
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Rcept of retrolective studies should be reinvestigated with respect
to potential sources of bias. Although the original idea of Fein-
stein14 on the first sight seems to be an interesting methodolog-
cal option to conduct clinical studies with the help of register
ata, several questions on study quality remain as putative flaws.
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